Ads
related to: docetaxel chemo- ENHERTU® Information
Learn More About ENHERTU® and How
it is Thought to Work.
- ENHERTU® Data
Access Important Data on How
ENHERTU® Performed in Studies.
- ENHERTU® Safety Info
Important Side Effect Information
for Patients and Caregivers.
- ENHERTU® Resources
Access Free Patient Resources Like
a Downloadable Brochure.
- ENHERTU® Information
Search results
Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Docetaxel Injection, USP Due to...
Tri-County Times· 6 days agoDocetaxel 160mg per 16mL
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday - Bristol-Myers Squibb (NYSE:BMY)
Benzinga· 15 hours agoAt a median follow-up of 9.4 months, Krazati demonstrated a statistically significant and clinically...
Bristol’s $250,000 pill slows lung cancer growth by 7 weeks
San Francisco Chronicle· 16 hours agoA Bristol Myers Squibb Co. lung cancer treatment delayed tumor growth by less than seven weeks in a closely watched clinical trial, a disappointing result after the company paid nearly $5 billion ...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks via Yahoo Finance· 6 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival...
Chemotherapy type can be personalized to decrease | Newswise
Newswise· 1 day agoTaxane-based chemotherapies are the primary curative therapy for breast cancer, but they can lead to...
No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC
MedPage Today· 2 days agoResults are 'disappointing as we need better therapies in the refractory space,' expert says
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 1 day agoThere is no control arm in this trial, but one can use the CLEOPATRA trial as a benchmark where the...
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Benzinga via Yahoo Finance· 6 days ago(NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial....
Phase 1/2 trial of the XPO1 inhibitor selinexor in | Newswise
Newswise· 6 days agoBackground: KRAS mutant NSCLC remains a therapeutic challenge. Although KRAS G12C inhibitors are now approved for cases harboring that specific mutation, t
Sagent Pharma Recalls Chemotherapy Drug Docetaxel Injection
RTT News· 5 days agoSagent Pharmaceuticals has recalled two lots of chemotherapy drug Docetaxel Injection, USP due to potential presence of particulate matter from the stopper in the drug, according to the U.
Ads
related to: docetaxel chemo
